Long-term human survival cohorts and Phase 3 prevention trials covering UKPDS 34 / TAME Metformin AMPK longevity pathways, muscle protein synthesis across eight decades of life, and adult vaccine coadministration trials. Explore 817 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
While the accuracy of observed outcomes across treatment arms was 82%, the accuracies of predicted.
In summary, getting both at the same time of DP + SP was associated with significantly reduced SP exposure, with a greater magnitude during the third vs.
Melatonin 3 mg is better than placebo for migraine prevention, more tolerable than amitriptyline and as effective as amitriptyline 25 mg.
One year of exercise increased late-phase postprandial GLP-1 response, which may prevent increased appetite after weight loss and thereby weight regain.
Olanzapine, in comparison with NK1 antagonist, is not superior for nausea control during carboplatin-induced emesis.
Structured exercise combined with glucagon-like peptide-1-based obesity pharmacotherapy led to clinically meaningful improvements in physical functional performance and cardiorespiratory fitness, in contrast to pharmacotherapy...
Ivarmacitinib 4 mg and 8 mg groups showed greater reductions in bone erosion and synovitis scores under MRI scanning from baseline to W24 versus the placebo group.
Ivarmacitinib 4 mg demonstrated consistent efficacy in patients with active AS across diverse demographic and clinical subgroups.
Fremanezumab demonstrated a favorable safety profile, with no safety signals.
BCG vaccine is safe and offers cross-protection against COVID-19 with potential humoral response modulation.
No significant differences in OS were observed between the ER and GE arms in all patients with EGFR mutation and those with brain.
Ibrutinib confirms efficacy in CLL patients at an early stage with an increased risk of progression.
Early ctDNA monitoring and modeling have the potential to significantly enhance treatment personalization.
We conclude that amlodipine does not affect circulating neurohormones and oxidative stress markers in patients with nonischemic cardiomyopathy treated with angiotensin-converting enzyme inhibitors, digoxin and diuretics.
There were no differences in progression-free survival between the patients with at least partial immunoglobulin recovery and the remaining population.
A single dose of MenACYW-TT was well tolerated, with a non-inferior seroresponse compared with MCV4-DT.
The primary endpoint is overall survival; secondary endpoints are progression-free survival, response rate, proportion with negative peritoneal washing cytology during chemotherapy, proportion requiring conversion surgery, and...
As an add-on booster to diet and exercise, liraglutide 3.0 mg was generally well tolerated and produced significantly greater reductions than placebo in AHI, body weight, SBP and HbA1c in participants with obesity and...
These findings suggest the need to reconsider maintenance therapy strategies after CCRT for potentially shifting away from cytotoxic chemotherapy towards alternative methods to enhance survival outcomes in patients with LACC.
Fever is one of the most common adverse reactions associated with vaccination and was observed in approximately half of the participants.
Early, short-term emollient use initiated in the neonatal period was associated with lower AD prevalence and severity at 5 years in high-risk children. Although the effect estimate remained similar following multiple imputation, uncertainty due to attrition remained.
Early initiation of tafamidis is associated with reduced mortality in patients with ATTR-CM, irrespective of initial LVEF value.
Lubiprostone was well tolerated and reduced liver fat content as measured by MRI-PDFF in patients with MASLD over 48 weeks.
The use of GLP1-RAs demonstrates efficacy in reducing BMI, triglycerides, waist circumference and total testosterone.
The 5-year cumulative incidence of relapse, event-free survival and overall survival were 5·5%, 92·3% and 96·3% respectively.
This study demonstrates that AV without anthracyclines is sufficient to achieve NSS and good survival in the majority of patients.
The analysis was performed on 174 women (median age, 48 years; range, 24-75 years) who had completed a cardiological assessment at 12 months and reached the end of treatment.
However, when the lymphoma group was analyzed separately, the ICD significantly reduced the peak OMAS-total score to a greater extent compared to IC (x̄ ± SD; 1.77 ± 1.59 vs.
Add-on treatment with sunitinib or sorafenib did not show an improvement in DFS or OS in patients with sRCC.
CH was frequent in patients with AA and its prevalence appeared to be higher at posttherapy timepoints than at diagnosis.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
